Nicaraguan antitrust authority approves acquisition of all shares held by FIFCO in Nicaraguan Brewing Holding, S.A

Rhea-AI Summary

Acepodia announced a strategic clinical collaboration with Pfizer Ignite to accelerate development of Acepodia's Antibody-Cell Conjugation (ACC) and allogeneic γδ2 T cell platforms into autoimmune diseases while continuing oncology programs. Pfizer Ignite will provide strategic guidance, clinical trial design, regulatory strategy and R&D resources. Acepodia said its lead candidate ACE1831 has shown a robust, durable effect in a Phase 1 first-in-human trial for non-Hodgkin's lymphoma after a single low dose. Under the agreement Acepodia retains all rights to program progress and future partnerships.

Positive

• Strategic collaboration with Pfizer Ignite to support clinical and regulatory work
• ACE1831 showed a robust, durable effect in a Phase 1 first-in-human trial
• Acepodia retains all rights to program progress and future partnerships

Negative

• Programs remain early-stage (Phase 1), with clinical validation still required
• No financial terms disclosed, leaving funding and commercialization details unclear

News Market Reaction

+0.37%

1 alert

+0.37% News Effect

On the day this news was published, TT gained 0.37%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Nicaraguan antitrust authority approves acquisition of all shares held by FIFCO in Nicaraguan Brewing Holding, S.A

Amsterdam, 15 January 2026 – HEINEKEN has been formally notified by the Nicaraguan antitrust authority (PROCOMPETENCIA) that the transaction involving the acquisition of the participation held by FIFCO in Nicaraguan Brewing Holding, S.A. has been approved, subject to the implementation of an antitrust compliance program in accordance with local regulations.

The completion of the previously announced transaction to acquire FIFCO’s beverage and retail businesses, as disclosed on 22 September 2025, is now expected to take place in Q1 2026. Further announcements will be made as appropriate.

Attachment

• Nicaraguan antitrust authority approves acquisition of all shares held by FIFCO in Nicaraguan Brewing Holding, S

FAQ

What did Acepodia announce with Pfizer Ignite on January 15, 2026 for HEINY?

Acepodia announced a strategic clinical collaboration with Pfizer Ignite to support development of ACC and γδ2 T cell platforms into autoimmune diseases while keeping oncology programs.

How will Pfizer Ignite support Acepodia's programs for HEINY?

Pfizer Ignite will provide strategic guidance, clinical trial design, regulatory strategy and R&D resources to accelerate development.

What clinical progress did Acepodia report for ACE1831 related to HEINY?

Acepodia reported that ACE1831 demonstrated a robust, durable effect in a Phase 1 first-in-human trial for non-Hodgkin's lymphoma after a single low dose.

Does Acepodia give up rights to the programs in the Pfizer Ignite deal for HEINY?

No; Acepodia retains all rights related to program progress and future partnership opportunities.

Does the Pfizer Ignite collaboration include financial terms or milestones for HEINY?

The announcement did not disclose any financial terms, milestones, or licensing fees.